Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin

Xenobiotica

Volumn 38, Issue 9, 2008, Pages 1240-1251

  Park, J E ^a   Kim, K B ^b   Bae, S K ^c   Moon, B S ^a   Liu, K H ^b,d   Shin, J G ^b,c  

^a CJ Corporation   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Inje University   (South Korea)

Author keywords

Atorvastatin; CYP3A5; Cytochrome P450 (CYP) 3A4; Human liver microsomes (HLMs); Para and ortho hydroxyatorvastatin

Indexed keywords

2 HYDROXYATORVASTATIN; 4 HYDROXYATORVASTATIN; ATORVASTATIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; ENZYME KINETICS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; TANDEM MASS SPECTROMETRY;

CYTOCHROME P-450 CYP3A; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KINETICS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; PYRROLES; RECOMBINANT PROTEINS;

EID: 50249098738     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802334391     Document Type: Article

References (25)

1. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, et al. 1996. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. Journal of the American Medical Association 275:128-133.
2. Fukuda T, Onishi S, Fukuen S, Ikenaga Y, Ohno M, Hoshino K, Matsumoto K, Maihara A, Momiyama K, Ito T, et al. 2004. CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics Journal 4:34-39.
3. Huang W, Lin YS, McConn II DJ, Calamia JC, Totah RA, Isoherranen N, Glodowski M, Thummel KE. 2004. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metabolism and Disposition 32:1434-1445.
4. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, Benet LZ, Christians U. 2000. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metabolism and Disposition 28:1369-1378.
5. Josephson F, Allqvist A, Janabi M, Sayi J, Aklillu E, Jande M, Mahindi M, Burhenne J, Bottiger Y, Gustafsson LL, et al. 2007. CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clinical Pharmacology and Therapy 81:708-712.
6. Kantola T, Kivisto KT, Neuvonen PJ. 1998. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clinical Pharmacology and Therapy 64:58-65.
7. Kearney AS, Crawford LF, Mehta SC, Radebaugh GW. 1993. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharmacology Research 10:1461-1465.
8. Kim KA, Park PW, Lee OJ, Choi SH, Min BH, Shin KH, Chun BG, Shin JG, Park JY. 2006. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clinical Pharmacology and Therapy 80:646-656.
9. Kim KA, Park PW, Lee OJ, Kang DK, Park JY. 2007. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. Journal of Clinical Pharmacology 47:87-93.
10. Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, Schwab M, Eichelbaum M, Strandberg T. 2004. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14:523-525.
11. Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE. 2002. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Molecular Pharmacology 62:162-172.
12. Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC, Lameire NH. 2003. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrology and Dial Transplant 18:967-976.
13. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. 1995. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arteriosclerosis and Thrombo-Vascular Biology 15:678-682.
14. Park JY, Kim KA, Park PW, Lee OJ, Kang DK, Shon JH, Liu KH, Shin JG. 2006. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clinical Pharmacology and Therapy 79:590-599.
15. Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH, Vyas KP. 1997. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metabolism and Disposition 25:1191-1199.
16. Raghubir N. 2006. Concurrent use of clopidogrel (Plavix) and atorvastatin (Lipitor) is contraindicated. South African Medical Journal 96:474.
17. Rodrigues AD. 1999. Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochemistry and Pharmacology 57:465-480.
18. Schachter M. 2005. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundamentals in Clinical Pharmacology 19:117-125.
19. Schrag ML, Wienkers LC. 2001. Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Drug Metabolism and Disposition 29:70-75.
20. Schuetz EG, Relling MV, Kishi S, Yang W, Das S, Chen P, Cook EH, Rosner GL, Pui CH, Blanco JG, et al. 2004. PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5. Pharmacology Reviews 56:159.
21. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapy 270: 414-423.
22. Warrington JS, Shader RI, Von Moltke LL, Greenblatt DJ. 2000. In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions. Drug Metabolism and Disposition 28:392-397.
23. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M. 1990. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Molecular Pharmacology 38:207-213.
24. Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T. 2004. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metabolism and Pharmacokinetics 19:120-129.
25. Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, et al. 2004. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clinical Pharmacology and Therapy 76:104-112.